SEATTLE, May 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced presentations of data on its development candidates, XYOTAX(TM) (paclitaxel poliglumex), pixantrone, and CT-2106 at the American Society of Clinical Oncology’s 2006 Annual Meeting, held June 2-6 in Atlanta, Georgia.
For a complete list of the CTI activities at ASCO, please see the table below. Date Time Abstract Title # Sat., June 3 8:00 AM 7578 Comparative trial of BBR 2778 poster (pixantrone) + rituximab vs. single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin’s lymphoma (NHL) Sat., June 3 8:00 AM 7039 Effect of gender on outcome in two poster randomized phase III trials of Noon paclitaxel poliglumex (PPX) in discussion chemo-naive patients with advanced NSCLC and poor performance status (PS2) Sat., June 3 8:00 AM 7040 Analysis of prognostic factors in poster patients with advanced Noon relapsed/refractory NSCLC: Cox discussion regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX) Sun., June 4 8:00 AM 7113 Analysis of prognostic factors in poster chemo-naive patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials Sun., June 4 2:00 PM 2015 Phase I trial of CT-2106 poster (polyglutamated camptothecin) 5:00 PM administered weekly in patients with discussion advanced solid tumors
For more information about the ASCO annual meeting, please refer to the conference website at http://www.asco.org/.
In addition, CTI is a co-sponsor of the annual meeting of Women Against Lung Cancer. The plenary session includes presentation from John E. Niederhuber, M.D., Deputy Director, NCI, on NCI’s plans for lung cancer and a panel discussion on estrogen and lung cancer including Jill M. Siegfried, Ph.D., from the University of Pittsburg Cancer Institute and Margaret Spitz, M.D., MPH, from The University of Texas M. D. Anderson Cancer Center. For more information, please refer to their website at http://www.womenagainstlungcancer.org/.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.
Cell Therapeutics, Inc.
CONTACT: investors, Leah Grant, +1-206-282-7100, or fax, +1-206-272-4434,or invest@ctiseattle.com, or media, Susan Callahan, +1-206-272-4472, orfax, +1-206-272-4434, or media@ctiseattle.com, both of Cell Therapeutics,Inc.
